Abstract: The present invention provides methods and compositions for attenuating expression of Fc?RIIA. In general, the described methodology involves the use of RNAi constructs that are targeted to a Fc?RIIA mRNA sequence.

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods, for producing the polypeptides of the present invention.

Abstract: It has been discovered that increasing telomerase activity in cells surrounding a wound has a variety of effects that enhance wound healing. Replication capacity is enhanced, and the mobility of the epithelial cells can be increased by 3-fold or more. Some aspects of the invention relate to agents that increase telomerase activity in cells at the site of the wound, promoting cells to move to the site and restore an epithelial layer and the underlying stratum. Other aspects of the invention relate to compositions comprising epithelial cells in which telomerase activity has been increased, useful as grafts for the treatment of wounds.

Abstract: The present invention is directed to compositions and methods related to the use of human OGC as an uncoupling protein.

Abstract: The invention relates to a process for the determination of the ?-secretase activity, individual components of the process and the use of the process. The present invention relates to a novel process for the determination of the ?-secretase activity and for the detection of ?-secretase; particular embodiments of the process relate on the one hand to processes for the identification of a ?-secretase or of a cDNA which codes for a ?-secretase and on the other hand to processes for the identification of substances which can inhibit the activity of a ?-secretase. Such substances have particular importance, as they can be used, for example, as pharmaceutical active compounds, e.g. for the treatment of Alzheimer's disease.

Abstract: The present invention provides a procaryotic host cell stably transformed or transfected by a vector including a DNA sequence encoding for mutant purine nucleoside phosphorylase or hydrolase. The transformed or transfected procaryotic host cell can be used in combination with a purine substrate to treat tumor cells and/or virally infected cells. The present invention provides nucleotide sequences encoding mutant E. coli derived purine nucleoside phosphorylase proteins which can be used in conjunction with an appropriate substrate to produce toxins which impair abnormal cell growth. The invention provides for delivery of the toxin by generation within target cells or by administration and delivery to the cells from without.

Abstract: Methods and compositions for diagnosing and treating glaucoma are disclosed.

Abstract: A gene trap vector comprises a DNA construct containing an expression unit of an internal ribosome binding site (IRES) coupled to a heterologous gene sequence; this expression unit is used in gene trap protocols to obtain expression of the heterologous gene in the host.

Abstract: This application is drawn to novel nucleic acid sequences encoding mammalian polypeptides that have sequence similarity to human angiopoietin-related proteins. The nucleic acid sequence is 1855 nucleotides long and contains an open reading frame from nucleotides 154-6 to 1369-71. The encoded polypeptides are about 405 amino acid residues in length.

Abstract: The invention relates to novel degradation resistant FGF-1, and methods for producing and using the same. More specifically, the invention relates to identification of a thrombin degradation resistant FGF-1, an a nucleic acid encoding the same. The thrombin degradation resistant FGF-1 can elicit responses that are otherwise typically impeded by degradation of FGF-1 by thrombin. Thrombin degradation resistant FGF-1 is an important molecule for effecting an FGF-1 response that would be otherwise inhibited by thrombin. Thus, the present invention provides a powerful therapeutic for diseases or disorders wherein an FGF-1 response can mediate a reduction in the frequency or intensity of a symptom of the disease or disorder but for degradation of FGF-1 before it can effect the response.

Abstract: The invention concerns the use of the apobec-1 protein or associated proteins for treating atherosclerosis and obesity, type II diabetes (non-insulin-dependent), or other diseases, characterised in particular by hyperlipidemia and/or hyperglycemia, caused for example by a level of chylomicrons and/or VLDL in the plasma above normal. The invention also concerns the cloning of the gene(s) of Anderson disease as target for treating atheroscelerosis, obesity and type II diabetes (non-insulin-dependent), or other diseases characterised in particular by hyperlipidemia and/or hyperglycermia.

Abstract: Presented are methods and compositions for targeted chromosomal genomic alterations using modified single-stranded oligonucleotides. The oligonucleotides of the invention have at least one modified nuclease-resistant terminal region comprising phosphorothioate linkages, LNA analogs or 2?-O-Me base analogs.

Abstract: Encapsulated producer cells which are capable of expressing a molecule which is an inhibitor of CNS tumour growth provide a novel approach to the treatment of tumours, such as brain tumors which are localized within the central nervous system.

Abstract: The invention provides a therapeutic composition for epithelial wound repair that is a combination of PDGF and KGF. Further, the invention provides a composition for epithelial wound repair that is a therapeutic combination of PDGF, KGF, and IGF. Additionally, the invention provides a therapeutic composition of PDGF, KGF, IGF and IGFBP for epithelial wound repair.

Abstract: Materials and Methods for treating fibrosis in a mammal are disclosed. The methods comprise administering to a mammal a composition comprising a therapeutically effective amount of a zvegf3 antagonist in combination with a pharmaceutically acceptable delivery vehicle. Zvegf3 antagonists include anti-zvegf3 antibodies, mitogenically inactive receptor-binding zvegf3 variant polypeptides, and inhibitory polynucleotides. Within one embodiment of the fibrosis is liver fibrosis.

Abstract: The present invention relates to a mycobacterial deoxyribonucleic acid (B-DNA) preserved and complexed on the mycobacterial cell wall (BCC) and a pharmaceutically acceptable carrier, wherein the BCC is effective in treating an inflammation in an animal having an inflammation. More particularly, the present invention relates to a Mycobacterium phlei deoxyribonucleic acid (M-DNA) preserved and complexed on Mycobacterium phlei cell wall (MCC) and a pharmaceutically acceptable carrier, wherein the MCC is effective in treating an inflammation in an animal having an inflammation.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Interferon gamma receptor 2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Interferon gamma receptor 2. Methods of using these compounds for modulation of Interferon gamma receptor 2 expression and for treatment of diseases associated with expression of Interferon gamma receptor 2 are provided.

Abstract: The invention provides sequence specific polynucleotide analogues and methods for determining the function of a nucleic acid of known sequence.

Abstract: A vector comprising a nucleotide sequence of interest (“NOI”) encoding a product of interest (“POI”) is described. The NOI and/or the POI is capable of recognizing a tumor, such that in use the vector is capable of delivering the NOI and/or the POI to the tumor.